The combination of SEA-CD40 with gemcitabine, nab-paclitaxel, and pembrolizumab demonstrated a 44% objective response rate in metastatic pancreatic ductal adenocarcinoma (PDAC).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.